No. That's part of why they're test is so expensive and their financials are so lackluster. They are apparently using a customized version of the lllumina's Global Screening Array according to their website and several other sources that show up in search results. That's a legit research quality genotyping platform from a world leading laboratory in the genetics space. This post from 2020 has a decent high level overview about it in the context of 23&me [0] though it might be slightly outdated by now and I've never heard of the company (xcode?) that wrote it (nor did I bother to look at what their product is.)
> If I was trying to launch a consumer DNA geneology service, I'd want to get network effects, so I'd want a test that was very easily affordable.
That's a pretty neive perspective. It ignores the value propositions of 23&me's product, economies of scale in the direct to consumer genetic testing space which were in large part enabled by 23&me's success, and all of the thorny bits related to questions about accuracy when presenting results. Not to mention that 23&me certainly capitalized on the network effect (which is being criticized a fair amount in this thread.)
> Who says their records are thorough enough to be valuable to drug companies?
GSK. See my other comment in this thread [1]
[0] https://www.xcode.life/23andme/23andme-v5-chip-dna-raw-data-...